Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases. / Bank, Steffen; Andersen, Paal Skytt; Burisch, Johan; Pedersen, Natalia; Roug, Stine; Galsgaard, Julie; Turino, Stine Ydegaard; Brodersen, Jacob Broder; Rashid, Shaista; Avlund, Sara; Olesen, Thomas ; Green, Anders; Hoffmann, Hans Jürgen; Thomsen, Marianne Kragh; Thomsen, Vibeke Østergaard; Nexø, Bjørn Andersen; Vogel, Ulla; Andersen, Vibeke.

In: Danish Medical Journal, Vol. 62, No. 3, 03.2015.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Bank, S, Andersen, PS, Burisch, J, Pedersen, N, Roug, S, Galsgaard, J, Turino, SY, Brodersen, JB, Rashid, S, Avlund, S, Olesen, T, Green, A, Hoffmann, HJ, Thomsen, MK, Thomsen, VØ, Nexø, BA, Vogel, U & Andersen, V 2015, 'Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases', Danish Medical Journal, vol. 62, no. 3.

APA

Bank, S., Andersen, P. S., Burisch, J., Pedersen, N., Roug, S., Galsgaard, J., ... Andersen, V. (2015). Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases. Danish Medical Journal, 62(3).

CBE

Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Avlund S, Olesen T, Green A, Hoffmann HJ, Thomsen MK, Thomsen VØ, Nexø BA, Vogel U, Andersen V. 2015. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases. Danish Medical Journal. 62(3).

MLA

Vancouver

Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J et al. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases. Danish Medical Journal. 2015 Mar;62(3).

Author

Bank, Steffen ; Andersen, Paal Skytt ; Burisch, Johan ; Pedersen, Natalia ; Roug, Stine ; Galsgaard, Julie ; Turino, Stine Ydegaard ; Brodersen, Jacob Broder ; Rashid, Shaista ; Avlund, Sara ; Olesen, Thomas ; Green, Anders ; Hoffmann, Hans Jürgen ; Thomsen, Marianne Kragh ; Thomsen, Vibeke Østergaard ; Nexø, Bjørn Andersen ; Vogel, Ulla ; Andersen, Vibeke. / Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases. In: Danish Medical Journal. 2015 ; Vol. 62, No. 3.

Bibtex

@article{cf53583476f543c391b38e419663de0a,
title = "Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases",
abstract = "Introduction: The objective of this study was to evaluate the outcome of anti-tumour necrosis factor-α (anti-TNF) treatment in a large cohort of patients with inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC) in clinical practice and to establish a cohort for future studies of genetic markers associated with treatment response.Methods: A national, clinically based cohort of previously na{\"i}ve anti-TNF treated patients from 18 medical departments was established. The patients were screened for tuberculosis prior to treatment initiation. By combining the unique personal identification number of Danish citizens (the CPR number) from blood samples with data from the National Patient Registry, patients with International Classification of Diseases, Version 10 (ICD-10) codes K50-K63 were identified. Treatment efficacy reflected the maximum response within 22 weeks.Results: Among 492 patients with CD and 267 patients with UC, 74{\%}/13{\%}/14{\%} and 65{\%}/12{\%}/24{\%} were responders, partial responders and non-responders to anti-TNF therapy, respectively. More patients with UC than with CD were non-responders (odds ratio (OR) = 1.96, 95{\%} confidence interval (CI): 1.34-2.87, p = 0.001). Young age was associated with a beneficial response (p = 0.03), whereas smoking ≥ 10 cigarettes/day was associated with non-response among patients with CD (OR = 2.33, 95{\%} CI: 1.13-4.81, p = 0.03).Conclusion: In this clinically based cohort of Danish patients with IBD treated with anti-TNF, high response rates were found. Heavy smoking was associated with non-response, whereas young age at treatment initiation was associated with a beneficial response among patients with CD. Thus, the results obtained in this cohort recruited from clinical practice were similar to those previously obtained in clinical trials.Funding: The work was funded by Health Research Fund of Central Denmark Region, Colitis-Crohn Foreningen and the University of Aarhus (PhD grant).Trial registration: Clinicaltrials NCT02322008.",
author = "Steffen Bank and Andersen, {Paal Skytt} and Johan Burisch and Natalia Pedersen and Stine Roug and Julie Galsgaard and Turino, {Stine Ydegaard} and Brodersen, {Jacob Broder} and Shaista Rashid and Sara Avlund and Thomas Olesen and Anders Green and Hoffmann, {Hans J{\"u}rgen} and Thomsen, {Marianne Kragh} and Thomsen, {Vibeke {\O}stergaard} and Nex{\o}, {Bj{\o}rn Andersen} and Ulla Vogel and Vibeke Andersen",
year = "2015",
month = "3",
language = "English",
volume = "62",
journal = "Danish Medical Bulletin (Online)",
issn = "1603-9629",
publisher = "Den Almindelige Danske L{\ae}geforening",
number = "3",

}

RIS

TY - JOUR

T1 - Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases

AU - Bank, Steffen

AU - Andersen, Paal Skytt

AU - Burisch, Johan

AU - Pedersen, Natalia

AU - Roug, Stine

AU - Galsgaard, Julie

AU - Turino, Stine Ydegaard

AU - Brodersen, Jacob Broder

AU - Rashid, Shaista

AU - Avlund, Sara

AU - Olesen, Thomas

AU - Green, Anders

AU - Hoffmann, Hans Jürgen

AU - Thomsen, Marianne Kragh

AU - Thomsen, Vibeke Østergaard

AU - Nexø, Bjørn Andersen

AU - Vogel, Ulla

AU - Andersen, Vibeke

PY - 2015/3

Y1 - 2015/3

N2 - Introduction: The objective of this study was to evaluate the outcome of anti-tumour necrosis factor-α (anti-TNF) treatment in a large cohort of patients with inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC) in clinical practice and to establish a cohort for future studies of genetic markers associated with treatment response.Methods: A national, clinically based cohort of previously naïve anti-TNF treated patients from 18 medical departments was established. The patients were screened for tuberculosis prior to treatment initiation. By combining the unique personal identification number of Danish citizens (the CPR number) from blood samples with data from the National Patient Registry, patients with International Classification of Diseases, Version 10 (ICD-10) codes K50-K63 were identified. Treatment efficacy reflected the maximum response within 22 weeks.Results: Among 492 patients with CD and 267 patients with UC, 74%/13%/14% and 65%/12%/24% were responders, partial responders and non-responders to anti-TNF therapy, respectively. More patients with UC than with CD were non-responders (odds ratio (OR) = 1.96, 95% confidence interval (CI): 1.34-2.87, p = 0.001). Young age was associated with a beneficial response (p = 0.03), whereas smoking ≥ 10 cigarettes/day was associated with non-response among patients with CD (OR = 2.33, 95% CI: 1.13-4.81, p = 0.03).Conclusion: In this clinically based cohort of Danish patients with IBD treated with anti-TNF, high response rates were found. Heavy smoking was associated with non-response, whereas young age at treatment initiation was associated with a beneficial response among patients with CD. Thus, the results obtained in this cohort recruited from clinical practice were similar to those previously obtained in clinical trials.Funding: The work was funded by Health Research Fund of Central Denmark Region, Colitis-Crohn Foreningen and the University of Aarhus (PhD grant).Trial registration: Clinicaltrials NCT02322008.

AB - Introduction: The objective of this study was to evaluate the outcome of anti-tumour necrosis factor-α (anti-TNF) treatment in a large cohort of patients with inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC) in clinical practice and to establish a cohort for future studies of genetic markers associated with treatment response.Methods: A national, clinically based cohort of previously naïve anti-TNF treated patients from 18 medical departments was established. The patients were screened for tuberculosis prior to treatment initiation. By combining the unique personal identification number of Danish citizens (the CPR number) from blood samples with data from the National Patient Registry, patients with International Classification of Diseases, Version 10 (ICD-10) codes K50-K63 were identified. Treatment efficacy reflected the maximum response within 22 weeks.Results: Among 492 patients with CD and 267 patients with UC, 74%/13%/14% and 65%/12%/24% were responders, partial responders and non-responders to anti-TNF therapy, respectively. More patients with UC than with CD were non-responders (odds ratio (OR) = 1.96, 95% confidence interval (CI): 1.34-2.87, p = 0.001). Young age was associated with a beneficial response (p = 0.03), whereas smoking ≥ 10 cigarettes/day was associated with non-response among patients with CD (OR = 2.33, 95% CI: 1.13-4.81, p = 0.03).Conclusion: In this clinically based cohort of Danish patients with IBD treated with anti-TNF, high response rates were found. Heavy smoking was associated with non-response, whereas young age at treatment initiation was associated with a beneficial response among patients with CD. Thus, the results obtained in this cohort recruited from clinical practice were similar to those previously obtained in clinical trials.Funding: The work was funded by Health Research Fund of Central Denmark Region, Colitis-Crohn Foreningen and the University of Aarhus (PhD grant).Trial registration: Clinicaltrials NCT02322008.

M3 - Journal article

VL - 62

JO - Danish Medical Bulletin (Online)

JF - Danish Medical Bulletin (Online)

SN - 1603-9629

IS - 3

ER -